Cargando…
Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione
CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955250/ https://www.ncbi.nlm.nih.gov/pubmed/24423344 http://dx.doi.org/10.1210/jc.2013-3399 |
_version_ | 1782307545324453888 |
---|---|
author | O'Reilly, Michael W. Taylor, Angela E. Crabtree, Nicola J. Hughes, Beverly A. Capper, Farfia Crowley, Rachel K. Stewart, Paul M. Tomlinson, Jeremy W. Arlt, Wiebke |
author_facet | O'Reilly, Michael W. Taylor, Angela E. Crabtree, Nicola J. Hughes, Beverly A. Capper, Farfia Crowley, Rachel K. Stewart, Paul M. Tomlinson, Jeremy W. Arlt, Wiebke |
author_sort | O'Reilly, Michael W. |
collection | PubMed |
description | CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS. PATIENTS AND METHODS: Eighty-six PCOS patients fulfilling Rotterdam diagnostic consensus criteria and 43 age- and body mass index-matched controls underwent measurement of serum androgens by tandem mass spectrometry and an oral glucose tolerance test with homeostatic model assessment of insulin resistance and insulin sensitivity index calculation. We analyzed 24-hour urine androgen excretion by gas chromatography/mass spectrometry. RESULTS: PCOS patients had higher levels of serum androgens and urinary androgen metabolites than controls (all P < .001). Within the PCOS cohort, both serum A and T were positively correlated with the free androgen index (T × 100/SHBG) and total androgen metabolite excretion (all P < .001). All subjects with T above the normal reference range [high T (HT)] also had high A (HA/HT group, n = 56). However, the remaining 30 patients had normal T levels, either in the presence of HA (HA/NT; n = 20) or normal A (NA/NT; n = 10). The groups did not differ in age or BMI. The HA/HT and HA/NT groups had higher total androgen excretion than NA/NT (P < .01 and P < .05, respectively). Multiple linear regression showed a strong negative association between serum androstenedione and insulin sensitivity. The incidence of dysglycemia according to an oral glucose tolerance test increased with the severity of androgen phenotype (NA/NT, 0%; HA/NT, 14%; HA/HT, 25%, P = .03). CONCLUSION: Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women. HA levels are a sensitive indicator of PCOS-related androgen excess. |
format | Online Article Text |
id | pubmed-3955250 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-39552502014-04-02 Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione O'Reilly, Michael W. Taylor, Angela E. Crabtree, Nicola J. Hughes, Beverly A. Capper, Farfia Crowley, Rachel K. Stewart, Paul M. Tomlinson, Jeremy W. Arlt, Wiebke J Clin Endocrinol Metab Endocrine Research CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS. PATIENTS AND METHODS: Eighty-six PCOS patients fulfilling Rotterdam diagnostic consensus criteria and 43 age- and body mass index-matched controls underwent measurement of serum androgens by tandem mass spectrometry and an oral glucose tolerance test with homeostatic model assessment of insulin resistance and insulin sensitivity index calculation. We analyzed 24-hour urine androgen excretion by gas chromatography/mass spectrometry. RESULTS: PCOS patients had higher levels of serum androgens and urinary androgen metabolites than controls (all P < .001). Within the PCOS cohort, both serum A and T were positively correlated with the free androgen index (T × 100/SHBG) and total androgen metabolite excretion (all P < .001). All subjects with T above the normal reference range [high T (HT)] also had high A (HA/HT group, n = 56). However, the remaining 30 patients had normal T levels, either in the presence of HA (HA/NT; n = 20) or normal A (NA/NT; n = 10). The groups did not differ in age or BMI. The HA/HT and HA/NT groups had higher total androgen excretion than NA/NT (P < .01 and P < .05, respectively). Multiple linear regression showed a strong negative association between serum androstenedione and insulin sensitivity. The incidence of dysglycemia according to an oral glucose tolerance test increased with the severity of androgen phenotype (NA/NT, 0%; HA/NT, 14%; HA/HT, 25%, P = .03). CONCLUSION: Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women. HA levels are a sensitive indicator of PCOS-related androgen excess. Endocrine Society 2014-03 2014-01-07 /pmc/articles/PMC3955250/ /pubmed/24423344 http://dx.doi.org/10.1210/jc.2013-3399 Text en Copyright © 2014 by The Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Endocrine Research O'Reilly, Michael W. Taylor, Angela E. Crabtree, Nicola J. Hughes, Beverly A. Capper, Farfia Crowley, Rachel K. Stewart, Paul M. Tomlinson, Jeremy W. Arlt, Wiebke Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title | Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title_full | Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title_fullStr | Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title_full_unstemmed | Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title_short | Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione |
title_sort | hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione |
topic | Endocrine Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955250/ https://www.ncbi.nlm.nih.gov/pubmed/24423344 http://dx.doi.org/10.1210/jc.2013-3399 |
work_keys_str_mv | AT oreillymichaelw hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT taylorangelae hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT crabtreenicolaj hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT hughesbeverlya hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT capperfarfia hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT crowleyrachelk hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT stewartpaulm hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT tomlinsonjeremyw hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione AT arltwiebke hyperandrogenemiapredictsmetabolicphenotypeinpolycysticovarysyndrometheutilityofserumandrostenedione |